ReviewPharmaceutical nanotechnology2025
Emulgel-Based Formulations of Clobetasol Propionate: Formulation Development, Characterization, and Pharmacological Evaluation.
Review in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical formulations of corticosteroids, particularly clobetasol propionate (CP), are commonly used to treat a range of dermatological conditions. CP is a potent corticosteroid known for its efficacy in managing inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Emulgel-based formulations of CP have emerged as an innovative approach, offering advantages like improved drug solubility, enhanced skin penetration, and extended drug release. This review aims to provide an updated overview of the latest advancements in the development and evaluation of CP emulgel formulations. Key aspects discussed include the selection and optimization of emulgel components, formulation characterization,
Indexed as
Identifiers
39980290What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.